{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:52:33Z","timestamp":1793508753710,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sumitomo Pharma America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.urology.2023.11.033","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T17:13:42Z","timestamp":1706548422000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment"],"prefix":"10.1016","volume":"186","author":[{"given":"Michael B.","family":"Chancellor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Lucioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.11.033_bib1","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","author":"Gormley","year":"2019","journal-title":"Am Urol Assoc"},{"key":"10.1016\/j.urology.2023.11.033_bib2","unstructured":"Janssen Pharmaceuticals: Ditropan XL: oxybutynin chloride extended release tablets. Titusville, NJ; 2016."},{"key":"10.1016\/j.urology.2023.11.033_bib3","first-page":"CD003193","article-title":"Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults","volume":"12","author":"Rai","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urology.2023.11.033_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00002512-200522120-00003","article-title":"Overactive bladder in the elderly: a guide to pharmacological management","volume":"22","author":"Staskin","year":"2005","journal-title":"Drugs Aging"},{"key":"10.1016\/j.urology.2023.11.033_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study","volume":"9","author":"Szabo","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.urology.2023.11.033_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/nau.24536","article-title":"Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis","volume":"40","author":"Dmochowski","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2023.11.033_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/UPJ.0000000000000243","article-title":"Yearly trends of overactive bladder medication usage","volume":"8","author":"Chua","year":"2021","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2023.11.033_bib8","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1007\/s12325-023-02625-8","article-title":"Patient and clinician challenges with anticholinergic step therapy in the treatment of overactive bladder: a narrative review","volume":"40","author":"Dmochowski","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2023.11.033_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.11.033_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.urology.2023.11.033_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.neuropharm.2017.09.011","article-title":"Physiological roles of CNS muscarinic receptors gained from knockout mice","volume":"136","author":"Thomsen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.urology.2023.11.033_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11597530-000000000-00000","article-title":"Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder","volume":"29","author":"Chancellor","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.urology.2023.11.033_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","article-title":"Anticholinergics for overactive bladder therapy: central nervous system effects","volume":"18","author":"Chancellor","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.urology.2023.11.033_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2125.2011.03961.x","article-title":"A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder","volume":"72","author":"Callegari","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.urology.2023.11.033_bib15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.urology.2023.11.033_bib16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","article-title":"Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder","volume":"64","author":"Staskin","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2023.11.033_bib17","article-title":"Differences in the brain penetration of the anticholinergic drugs trospium chloride and oxybutynin","volume":"3(1)","author":"Geyer","year":"2010","journal-title":"UroToday Int J"},{"key":"10.1016\/j.urology.2023.11.033_bib18","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.108.136390","article-title":"In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment","volume":"325","author":"Maruyama","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.urology.2023.11.033_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lfs.2010.06.008","article-title":"Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography","volume":"87","author":"Yoshida","year":"2010","journal-title":"Life Sci"},{"key":"10.1016\/j.urology.2023.11.033_bib20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1532-5415.2010.03011.x","article-title":"The blood-brain barrier: geriatric relevance of a critical brain-body interface","volume":"58","author":"Zeevi","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.urology.2023.11.033_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s002400050169","article-title":"Oxybutynin disrupts learning and memory in the rat passive avoidance response","volume":"27","author":"Sugiyama","year":"1999","journal-title":"Urol Res"},{"key":"10.1016\/j.urology.2023.11.033_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejphar.2006.11.054","article-title":"Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test","volume":"557","author":"Suzuki","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.urology.2023.11.033_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1254\/jjp.87.27","article-title":"Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats","volume":"87","author":"Oka","year":"2001","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.urology.2023.11.033_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2011.06.031","article-title":"Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [(11)C](+)3-MPB","volume":"58","author":"Yamamoto","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/j.urology.2023.11.033_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","article-title":"Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers","volume":"47","author":"Pietzko","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.urology.2023.11.033_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.urology.2023.11.033_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14740330903260790","article-title":"Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg","volume":"8","author":"Wesnes","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.urology.2023.11.033_bib28","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1464-410X.2005.05296.x","article-title":"Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years","volume":"95","author":"Diefenbach","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.11.033_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.11.033_bib30","first-page":"151","article-title":"Oxybutynin extended release for the management of overactive bladder: a clinical review","volume":"3","author":"Arisco","year":"2009","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.urology.2023.11.033_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.11.033_bib32","unstructured":"Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects. Accessed September 17, 2022. \u3008https:\/\/www.ics.org\/Abstracts\/Publish\/44\/000087.pdf\u3009."},{"key":"10.1016\/j.urology.2023.11.033_bib33","first-page":"321","article-title":"Insights into the management of overactive bladder with transdermal oxybutynin: a practical review","volume":"12","author":"Vozmediano-Chicharro","year":"2020","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urology.2023.11.033_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF03261924","article-title":"Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study","volume":"32","author":"Kay","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.urology.2023.11.033_bib35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jalz.2012.12.002","article-title":"Exploration of 100 commonly used drugs and supplements on cognition in older adults","volume":"9","author":"Obermann","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.urology.2023.11.033_bib36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/pds.5480","article-title":"Risk of delirium associated with antimuscarinics in older adults: a case-time-control study","volume":"31","author":"Nishtala","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.urology.2023.11.033_bib37","article-title":"Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2023.11.033_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/JU.0000000000002804","article-title":"Dementia associated with anticholinergic drugs used for overactive bladder: a nested case-control study using the french national medical-administrative database","volume":"208","author":"Malcher","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.11.033_bib39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2023.11.033_bib40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ageing\/afaa090","article-title":"Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis","volume":"49","author":"Pieper","year":"2020","journal-title":"Age Ageing"},{"key":"10.1016\/j.urology.2023.11.033_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.11.033_bib42","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.urology.2023.11.033_bib43","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/nau.25037","article-title":"SUFU white paper on overactive bladder anticholinergic medications and dementia risk","volume":"41","author":"Zillioux","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2023.11.033_bib44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.euf.2022.08.002","article-title":"The differential risk of mortality among users of overactive bladder anticholinergic medications and \u03b23 agonists","volume":"9","author":"Welk","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2023.11.033_bib45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/SPV.0000000000001272","article-title":"Overactive bladder and cognitive impairment: the American Urogynecologic Society and Pelvic Floor Disorders Research Foundation state-of-the-science conference summary report","volume":"29","author":"Dengler","year":"2023","journal-title":"Urogynecology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429524000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:49:28Z","timestamp":1713401368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429524000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":45,"alternative-id":["S0090429524000062"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.11.033","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.11.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.12.022","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}